Skip to main navigation

News
Alerts
Careers
Contact

About
Pipeline
Rezafungin
Cloudbreak
- Overview
- ADC
Publications
Investors
Secondary Investor Relations

Press enter to begin your search

Home
About
Drug Candidates
- Pipeline
- CD101 IV
- CD101 Topical
- C001
- Publications
Cloudbreak
Opportunity
Investors
Secondary Investor Relations
Contact

Event Calendar

Event Calendar

UPCOMING EVENTS

More events are coming soon.

NAVIGATION

Overview
Financials
- SEC Filings
Stock Information
Corporate Governance
News & Events
Analyst Coverage
Shareholder Services

Tool Kit

	Print Page
	RSS Feeds
	E-mail Alerts

Get Important News and Updates by Email Subscribe

About Cidara

Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives and immunotherapies that have the potential to transform the standard of care and save or improve patients' lives.
Learn more >>

Recent News

Cidara Therapeutics Appoints James Levine as CFO and Jessica Oien as General Counsel and Secretary

December 3, 2018

Cidara Therapeutics to Present New Data at ASH 2018 Highlighting Potential of Rezafungin to Prevent Invasive Fungal Infections in Bone Marrow Transplant Patients

November 27, 2018

Cidara Therapeutics Named a San Diego Metro Area Top Workplace for Second Consecutive Year

November 12, 2018

Navigation

Secondary Investor Relations

Overview
Presentations
Financials
Stock Information
Corporate Governance
News & Events
Analyst Coverage
Shareholder Services

Contact Us

Cidara Therapeutics, Inc.
6310 Nancy Ridge Drive, Suite 101
San Diego, CA 92121
Tel: (858) 752-6170
Email: info@cidara.com

© 2018 Cidara Therapeutics, Inc. | Terms of Use | Privacy Policy

Quick Links

Secondary Investor Relations

Overview
Presentations
Financials
Stock Information
Corporate Governance
News & Events
Analyst Coverage
Shareholder Services

Tweets by @CidaraThera